Back to News
Market Impact: 0.48
Vera's TRUTAKNA Shows Two-Year Kidney Protection; SBLA Planned Q4 2026; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Vera Therapeutics reported that TRUTAKNA stabilized kidney function and prevented disease progression over two years in adults with primary IgA nephropathy in the pivotal ORIGIN 3 trial. The positive long-term pivotal-study outcome materially strengthens the therapy's clinical profile and could support its commercial and regulatory outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
VERA0.90
More News
- Why is Vera Therapeutics stock reversing its premarket gains?
- Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
- Grab aims for 'next level' in financial services with purchase of buy-now pay-later platform Atome
- China's AI leaders keep quiet despite U.S. 'publicity' on tech risks
- Exclusive-Malaysia talks to rival airlines as it monitors AirAsia’s financial health, sources say
- Is Amazon Stock a Buy After Its Best Quarter in Years?